Evidence map›Paper›PMID 28409285›Full record

Trial reportEuropean journal of pediatrics2017

Urinary calprotectin, kidney injury molecule-1, and neutrophil gelatinase-associated lipocalin for the prediction of adverse outcome in pediatric acute kidney injury.

Jens H Westhoff, Felix S Seibert, Sina Waldherr, Frederic Bauer, Burkhard Tönshoff, Alexander Fichtner, Timm H Westhoff

Abstract readClinical TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in European journal of pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Gut microbiota and neonatal acute kidney injury biomarkers.Pediatric nephrology (Berlin, Germany) · 2023
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Observational
  19. Observational
  20. Urinary NMR Profiling in Pediatric Acute Kidney Injury-A Pilot Study.International journal of molecular sciences · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jens H WesthoffDepartment of Pediatrics I, University Children's Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany. jens.westhoff@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0002-9837-9383
Felix S SeibertMedical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University of Bochum, Bochum, Germany.
Sina WaldherrDepartment of Neonatology, University Children's Hospital, Heidelberg, Germany.
Frederic BauerMedical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University of Bochum, Bochum, Germany.
Burkhard TönshoffDepartment of Pediatrics I, University Children's Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.
Alexander FichtnerDepartment of Pediatrics I, University Children's Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.
Timm H WesthoffMedical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University of Bochum, Bochum, Germany.
Heidelberg University · DEUniversitätsklinik Marien Hospital Herne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early identification of patients with acute kidney injury (AKI) being at high risk for adverse outcome can influence medical treatment. This study compares urinary calprotectin, kidney injury molecule-1 (KIM-1), and neutrophil gelatinase-associated lipocalin (NGAL) for their performance in predicting mortality and need for renal replacement therapy (RRT) in pediatric AKI patients. Urinary biomarker concentrations were assessed prospectively in 141 subjects aged 0-18 years including 55 patients with established AKI according to pediatric Risk, Injury, Failure, Loss, and End-stage kidney disease (pRIFLE) criteria, 27 patients without AKI, and 59 healthy children. Within the AKI group, receiver operating characteristic (ROC) curve analysis revealed moderate to poor performance of calprotectin and KIM-1 in the prediction of 30-day mortality (calprotectin area under the curve (AUC) 0.55; KIM-1 AUC 0.55) and 3-month mortality (calprotectin AUC 0.61; KIM-1 AUC 0.60) and fair performance in the prediction of RRT requirement (calprotectin AUC 0.72; KIM-1 AUC 0.71). Urinary NGAL showed good performance in predicting 30-day (AUC 0.79) and 3-month (AUC 0.81) mortality and moderate performance in predicting RRT (AUC 0.61).

conclusionsWhereas urinary calprotectin and KIM-1 can be useful for the prediction of RRT, urinary NGAL has a good diagnostic performance in predicting mortality in pediatric patients with AKI of heterogeneous etiology. What is known: • There is increasing evidence that urinary biomarkers like neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) are valuable for the prediction of adverse outcome in adult acute kidney injury (AKI), whereas data on pediatric AKI is scarce. What is new: • Urinary calprotectin and KIM-1 do not predict mortality in our heterogeneous pediatric AKI cohort, but they show moderate performance in the prediction of dialysis. • Urinary NGAL is a good predictor of mortality performing better than pRIFLE stage, eGFR, or creatinine, but it shows moderate performance in the prediction of dialysis.

Indexed as

Acute Kidney InjuryAdolescentBiomarkersChildChild, PreschoolCross-Sectional StudiesDecision Support TechniquesFemaleHepatitis A Virus Cellular Receptor 1HumansInfantInfant, NewbornLeukocyte L1 Antigen ComplexLipocalin-2MalePrognosisBiomarkersHAVCR1 protein, humanHepatitis A Virus Cellular Receptor 1LCN2 protein, humanLeukocyte L1 Antigen ComplexLipocalin-2Acute kidney injuryBiomarkerCalprotectinKidney injury molecule-1Neutrophil gelatinase-associated lipocalinPediatric

Identifiers

PMID28409285
OpenAlexW2605522093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.